Arrowhead Pharmaceuticals (NASDAQ:ARWR) is a biopharmaceutical company focused on developing medicines that treat intractable diseases by silencing the genes that cause them. The company is known for its innovative approach to RNA interference (RNAi) therapeutics. Arrowhead competes with other biotech firms in the RNAi space, such as Alnylam Pharmaceuticals and Ionis Pharmaceuticals.
On January 5, 2026, Hamilton James C, the Chief Medical Officer of ARWR, sold 4,625 shares at $61.24 each. This transaction was reported on Form 4, a document used by company insiders to report their trades. After this sale, Hamilton James C still holds 207,497 shares. This insider activity is publicly available on the SEC website.
Mauro Ferrari, a Director at Arrowhead, also recently sold shares. He sold 7,530 shares at an average price of $70, totaling $527,100. After this sale, Ferrari owns 69,053 shares, valued at about $4.83 million. This sale reduced his ownership by 9.83%. Previously, on November 28th, he sold 8,750 shares at $56.39 each, totaling $493,412.50.
Arrowhead's stock opened at $66.39 in the latest trading session, a 1.3% decrease. The stock is currently priced at $63.88, down 5.77% or $3.91. It has fluctuated between $60.62 and $68 during the day. Over the past year, the stock has seen a high of $72.36 and a low of $9.57. The company's market cap is around $8.83 billion.
The trading volume for ARWR today is 2,692,400 shares. The stock's 50-day moving average is $53.54, indicating recent upward momentum. Despite recent insider sales, Arrowhead remains a significant player in the biopharmaceutical industry, with a focus on RNAi therapeutics.
